Haleon (HLN) Non Operating Interest Expenses (2021 - 2025)
Haleon's (HLN) quarterly Non Operating Interest Expenses came in at -$235.8 million in Q4 2025, up 36.46% on a QoQ basis from -$371.1 million in Q4 2023.
Haleon (HLN) Non Operating Interest Expenses (2021 - 2025) Analysis & Trends
Haleon (HLN) has 4 years of Non Operating Interest Expenses data on file, last reported at -$235.8 million in Q4 2025.
- Quarterly Non Operating Interest Expenses changed N/A year-over-year to -$235.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$878.2 million (changed N/A YoY) and the FY2024 annual result came in at -$490.9 million, up 1.83% from the prior year.
- Non Operating Interest Expenses improved to -$235.8 million in Q4 2025, from -$371.1 million in the prior quarter.
- In the past five years, Non Operating Interest Expenses ranged from a high of -$18.9 million in Q4 2021 to a low of -$371.1 million in Q4 2023.
- A 4-year average of -$155.3 million and a median of -$116.2 million in 2023 frame the typical range for Non Operating Interest Expenses.
- Annual changes were most pronounced in 2022 — Non Operating Interest Expenses plunged 391.0% — and 2023, when it plunged 300.5%.
- Tracing HLN's Non Operating Interest Expenses over 4 years: stood at -$18.9 million in 2021, then sank by 391.0% to -$92.7 million in 2022, then plunged by 300.5% to -$371.1 million in 2023, then jumped by 36.46% to -$235.8 million in 2025.
- The last three Non Operating Interest Expenses figures came in at -$235.8 million (Q4 2025), -$371.1 million (Q4 2023), and -$155.2 million (Q2 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.85 Bn | 42.88 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.31 Bn | 39.66 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.65 Bn | 29.98 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | -400.56 Mn |
| 5 | United Therapeutics | 22.18 Bn | 19.52 Bn | 683.80 Mn | 2.90 Mn |
| 6 | Viatris | 18.82 Bn | 17.94 Bn | 1.46 Bn | 120.70 Mn |
| 7 | Neurocrine Biosciences | 15.70 Bn | 15.31 Bn | 935.80 Mn | 2.90 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Alkermes | 8.21 Bn | 7.55 Bn | 397.90 Mn | 25.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -235.81 Mn |
| Dec 31, 2023 | -371.10 Mn |
| Jun 30, 2023 | -155.17 Mn |
| May 3, 2023 | -116.16 Mn |
| Dec 31, 2022 | -92.66 Mn |
| Sep 20, 2022 | -97.27 Mn |
| Dec 31, 2021 | -18.87 Mn |